Yu Dai
Xinyu Luo1,2†
Jin Yan- 1Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
- 2School of Medicine, University of Electronic Science and Technology of China, Sichuan Cancer Hospital, Chengdu, Sichuan, China
- 3Department of Abdominal Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital Affiliated to University of Electronic Science and Technology of China, Chengdu, Sichuan, China
Colorectal cancer (CRC) exhibits a striking dichotomy in response to immune checkpoint inhibitors (ICIs), with durable benefit largely restricted to dMMR/MSI-H disease while most pMMR/MSS tumors remain refractory. Central to this resistance is an immunosuppressive myeloid ecosystem—dominated by SPP1high tumor-associated macrophages, neutrophils/PMN-MDSCs, and LAMP3+ mregDCs—that enforces chemokine-driven exclusion, attenuates antigen presentation, and sustains metabolite-mediated T-cell suppression. Despite advances in checkpoint blockade and biomarker stratification, these microenvironmental circuits constitute a major therapeutic hurdle. Moreover, single-cell and spatial proteomic platforms (e.g., CITE-seq, CODEX, imaging mass cytometry) now resolve the composition and topology of suppressive neighborhoods and highlight their utility for patient stratification and pharmacodynamic monitoring. This mini review summarizes cellular and spatial mechanisms by which myeloid states drive ICI non-response in CRC, emphasizing stromal TGF-β–coupled SPP1+ TAM programs, granulocytic chemokine axes (CXCL1/2–CXCR2; IL-8–CXCR1/2), and mregDC-mediated co-inhibition. We outline current and emerging myeloid-reprogramming strategies—including PI3Kγ and CSF1–CSF1R targeting, TREM2 antagonism, COX-2–PGE2 blockade, and adenosine-axis inhibition—and their integration with PD-(L)1 therapy, alongside single-cell/spatial endpoints to quantify on-treatment remodeling. The purpose of this mini-review is to provide a mechanistic and technology-informed framework to reference rational trial design and clinical translation for overcoming checkpoint resistance in CRC.
1 Introduction
Colorectal cancer (CRC) illustrates a marked dichotomy in responsiveness to immune checkpoint inhibitors (ICIs): durable clinical benefit is largely confined to the mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) subset, whereas the majority of mismatch repair–proficient/microsatellite-stable (pMMR/MSS) tumors fail to respond (1–3). This disparity reflects fundamental differences in tumor–immune ecology and has motivated concerted efforts to define tractable barriers to T-cell–directed immunotherapy in CRC (4–6). In parallel, molecular taxonomies such as the consensus molecular subtypes (CMS) emphasize that mesenchymal, TGF-β–rich stromal programs (e.g., CMS4) coexist with immune-inflamed (CMS1) states (7–9), reinforcing the premise that context-specific microenvironmental circuits shape antitumor immunity and therapeutic outcome.
A convergent body of evidence implicates immunosuppressive myeloid populations—tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), neutrophils, and mature dendritic cells enriched in immunoregulatory molecules (mregDCs)—as dominant effectors of checkpoint inhibitor non-response (10–12). These lineages constrain priming and execution of cytotoxic T-cell responses through impaired antigen presentation, nitric-oxide/reactive oxygen species programs, checkpoint ligand upregulation, and tolerogenic cytokine/eicosanoid/adenosine networks. Single-cell atlases in CRC further resolve functionally distinct myeloid states; for example, SPP1high macrophages that interact with fibroblast activation protein (FAP)+ cancer-associated fibroblasts and align with desmoplastic, T-cell–excluded niches (13, 14). Spatially resolved proteomic imaging corroborates that these myeloid programs assemble into reproducible “cellular neighborhoods”—recurrent, analytically defined arrangements of cell types within fixed spatial radii—at the invasive front that stratify antitumor immunity and prognosis (15–17).
Non-response phenotypes also track with granulocytic axes. Across tumor types, elevated systemic and intratumoral IL-8 (CXCL8) associates with reduced benefit from PD-(L)1 blockade, consistent with neutrophil/MDSC-mediated suppression (18, 19). In CRC, clinicopathologic inflammation and neutrophil enrichment correlate with resistance even among dMMR/MSI-H cases, underscoring that myeloid circuits can override high neoantigen load. These observations place chemokine pathways such as CXCL1/2–CXCR2, CCL2–CCR2, and IL-8–CXCR1/2—and their downstream effector programs—at the center of immune exclusion in CRC.
Methodological advances now enable rigorous deconvolution of myeloid heterogeneity and its spatial organization in human CRC. High-parameter single-cell RNA sequencing coupled to protein measurements has delineated TAM, dendritic, and neutrophil states linked to therapeutic sensitivity and resistance, and has provided mechanistic readouts for experimental perturbations (20, 21). Spatial proteomics platforms—including co-detection by indexing (CODEX) and imaging mass cytometry (IMC)—quantify dozens of proteins per cell in situ, allowing direct mapping of immune–stromal interfaces (22, 23), ligand–receptor topologies, and suppressive niches at single-cell resolution.
These insights nominate myeloid reprogramming as a rational complement to ICIs in CRC. Targetable nodes include PI3Kγ, a macrophage-intrinsic signaling switch whose inhibition restores inflammatory antigen presentation and augments checkpoint blockade; the CSF1–CSF1R axis that maintains immunosuppressive TAM pools; TREM2, a myeloid checkpoint whose blockade reshapes TAM states and synergizes with PD-1 therapy; and metabolic circuits such as COX-2–PGE2 and adenosine (CD39/CD73–A2A/A2B) that tonically enforce T-cell suppression. This review synthesizes current understanding of immunosuppressive myeloid states in CRC non-response to ICIs, with two aims: first, to integrate single-cell and spatial proteomic evidence that defines the composition and architecture of suppressive niches in human tumors; and second, to evaluate reprogramming strategies that target these myeloid circuits to convert immune-excluded CRC into ICI-responsive disease. The intent is to provide a mechanistic and technology-informed framework to guide study design and clinical translation in CRC immunotherapy.
2 Landscape of immunosuppressive myeloid states in colorectal cancer
Across colorectal tumors, the immunosuppressive myeloid compartment comprises lineage-defined populations—tumor-associated macrophages, neutrophils/PMN-MDSCs, monocytic-MDSCs, and dendritic cells—and finer “states” defined by transcriptional and protein markers shared across these cells. As shown in Figure 1, single-cell profiling in human CRC delineates macrophage states that diverge from the canonical M1/M2 schema; among these, SPP1high macrophages are consistently expanded and associate with extracellular matrix remodeling, VEGF/EGF signaling, and chemokine outputs that favor T-cell exclusion (24, 25). While transcriptomic data indicate that these cells are typically enriched for immunoregulatory transcripts such as TREM2, ARG1, IL10 and PD-L1. Within this framework, SPP1high macrophages—predominantly monocyte-derived and overlapping with but not identical to classical M2-like TAMs—are consistently expanded, with evidence for angiogenic versus matrix-remodeling SPP1+ subclusters that mirror analogous populations in other gastrointestinal malignancies. Spatial analyses demonstrate that SPP1high macrophages colocalize with fibroblast activation protein (FAP)+ cancer-associated fibroblasts at the invasive front, forming a mesenchymal–myeloid circuit linked to desmoplasia, poor cytotoxic infiltration, and adverse outcome (26, 27). These observations situate SPP1high macrophages as a central suppressive node in CRC.
Figure 1. Immunosuppressive myeloid–stromal crosstalk underlying PD-1/PD-L1 resistance in the CRC tumor microenvironment.
Granulocytic axes are prominent in CRC immune evasion. Neutrophils and PMN-MDSCs accumulate through CXCL1/2–CXCR2 and IL-8/CXCR1/2 signaling, amplify reactive oxygen species and arginase programs, and enforce immune exclusion. Pharmacologic and genetic perturbations across gastrointestinal and colitis-associated models demonstrate that CXCR2 signaling governs granulocytic recruitment and tumor promotion, providing mechanistic support for therapeutic targeting of this pathway (28, 29). Clinically, elevated circulating IL-8 tracks with inferior outcomes to PD-(L)1 blockade across malignancies, consistent with a neutrophil-dominated suppressive milieu that can supersede high tumor antigenicity (30, 31). In CRC, emergent data nominate combined CCR1/CXCR2 blockade to curtail protumor myeloid trafficking, underscoring the therapeutic relevance of chemokine circuits (32, 33).
Dendritic cell lineages in CRC encompass conventional DC1/2 and a mature LAMP3+ state enriched in immunoregulatory molecules (mregDC) that upregulates PD-L1, PD-L2 and other tolerogenic mediators while retaining antigen-presentation machinery (34, 35). This program, induced upon tumor-antigen uptake, supports T-cell priming in a context that simultaneously delivers checkpoint and cytokine-based inhibitory signals, thereby tuning effector differentiation and exhaustion. These DC states participate in structured cellular neighborhoods identified by multiplexed imaging; CRC tissues harbor myeloid-attracting hubs at the tumor–luminal interface and MMRd-enriched immune hubs within tumor nests (36, 37), each with characteristic myeloid–lymphoid assemblies that stratify prognosis and therapeutic sensitivity.
CRC harbors a reproducible landscape of suppressive myeloid states anchored by SPP1high tumor-associated macrophages, CXCR2-driven granulocytic programs, and mregDC modules. Single-cell and spatial studies converge on the concept that these populations assemble into mesenchymal-skewed, chemokine-rich niches that impede T-cell recruitment and function (38, 39). These features provide mechanistic context for checkpoint inhibitor non-response in pMMR/MSS disease.
3 Single-cell and spatial proteomics for mapping suppressive niches
Single-cell multi-omic profiling and high-plex spatial proteomics provide complementary resolution on how immunosuppressive myeloid programs are organized in colorectal cancer (40, 41). Antibody-tagged single-cell transcriptomics (CITE-seq, REAP-seq) jointly quantifies transcripts and surface proteins, enabling direct measurement of checkpoint ligands, antigen-presentation molecules, chemokine receptors, and myeloid differentiation markers within the same cells and thereby resolving SPP1high TAMs, mregDCs, and granulocytic states with reduced label ambiguity (42, 43). As shown in Table 1, these platforms define intracellular programs, whereas high-parameter imaging modalities capture the topologies that enforce T-cell exclusion. CITE-seq and REAP-seq are established for simultaneous RNA–protein readouts and support robust annotation of myeloid states that are otherwise weakly separable by mRNA alone.
Table 1. Single-cell and spatial proteomic platforms for delineating immunosuppressive niches in colorectal cancer.
Multiplexed spatial imaging has established that CRC assembles reproducible “cellular neighborhoods” at the invasive front in which myeloid, stromal, and lymphoid elements co-cluster. Using 56-marker CODEX on CRC tissue microarrays, Some studies identified coordinated neighborhoods whose composition stratified immune pressure and outcome, directly implicating organized myeloid–stromal hubs in immune control (44–46). Spatial multi-omic analyses consistently show tight coupling of SPP1+ macrophages with FAP+ cancer-associated fibroblasts, a mesenchymal–myeloid circuit linked to extracellular-matrix remodeling and T-cell exclusion in independent CRC cohorts and validated by spatial transcriptomics and immunofluorescence (47, 48). Three-dimensional high-plex atlases further reveal gradients and barriers not apparent in two dimensions, quantify cell–cell distances (49, 50), and uncover nested suppressive structures that align with histologic fronts and glandular architecture in CRC.
These spatial readouts contextualize mechanistic nodes relevant to non-response. Lymphatic-adjacent Treg–mregDC niches form immunoregulatory hubs that restrict antigen access and can be quantified by CODEX/IMC to nominate actionable checkpoints and cytokine axes. Spatially mapped TGF-β activity aligns with induction of immunosuppressive SPP1+ macrophages and impaired T-cell recruitment, reinforcing a dual stromal–myeloid barrier that is measurable with multiplexed imaging and suitable for pharmacodynamic monitoring in trials that combine myeloid-reprogramming agents with PD-(L)1 blockade.
4 Mechanistic circuits connecting myeloid programs to checkpoint inhibitor failure
CRC non-response to ICIs maps to stromal–myeloid circuits that restrict T-cell access, blunt priming, and attenuate effector function. Single-cell and spatial analyses position SPP1high tumor-associated macrophages in tight contact with FAP+ cancer-associated fibroblasts at the invasive front, enriched for extracellular-matrix and TGF-β signaling; this configuration aligns with immune-excluded architecture and adverse outcome (51, 52). Functional inference and experimental data support SPP1–CD44 and TGF-β–SMAD2/3/4 programs, coupled to PI3Kγ–AKT signaling and integrated with CSF1, CXCL12, CCL2, VEGF, and complement components, which stabilize SPP1+/TREM2+ macrophage identity, skew antigen presentation, and exclude cytotoxic lymphocytes (53, 54). In immune-excluded tumors, stromal TGF-β blockade restores intratumoral T-cell penetration and sensitizes to PD-(L)1 therapy, nominating this mesenchymal–myeloid axis as a proximal cause of checkpoint failure.
Chemokine pathways couple granulocytic recruitment to resistance. CXCL1/2–CXCR2 and IL-8/CXCR1/2 signaling drive accumulation of neutrophils and PMN-MDSCs that generate reactive oxygen species and arginase programs, degrade chemokine gradients, and physically occlude T-cell entry (55, 56). Clinically, elevated baseline or on-treatment IL-8 tracks with reduced benefit from PD-(L)1 blockade across solid tumors, supporting IL-8/CXCR2 as a resistance biomarker and therapeutic target; CXCR2 inhibition increases effector T-cell infiltration and potentiates immunotherapy in preclinical models (57, 58).
Antigen handling and co-inhibitory signaling by dendritic cells constitute a second node linking myeloid states to non-response. Mature, migratory LAMP3+ dendritic cells (mregDCs) upregulate PD-L1/PD-L2 and immunoregulatory cytokines while preserving antigen-presentation machinery (59, 60); in tumors, these cells accumulate at lymphoid–stromal interfaces where they support constrained priming and program T-cell exhaustion under high checkpoint ligand density.
Macrophage-intrinsic signaling and metabolic circuits sustain these barriers and directly antagonize PD-1–directed reinvigoration. PI3Kγ signaling in macrophages enforces a C/EBPβ-driven program that suppresses antigen presentation and promotes IL-10/ARG1 output; pharmacologic PI3Kγ inhibition reprograms TAMs and synergizes with PD-1 blockade. TREM2+ lipid-associated TAMs curtail T-cell function, and anti-TREM2 augments PD-1 therapy in resistant settings (61, 62). COX-2–PGE2 signaling and PMN-MDSC-intrinsic FATP2-dependent arachidonic-acid metabolism amplify PGE2 production, reinforce myeloid suppression, and reduce responsiveness to ICIs; early clinical experience indicates feasibility of combining COX inhibition with PD-1 in MSI-H CRC (63, 64). Adenosine produced through CD39/CD73 engages A2A/A2B receptors on myeloid and lymphoid cells to blunt effector responses, implicating ectonucleotidases and adenosine-receptor antagonists as complementary approaches (65, 66). In CRC models, CSF1R inhibition reprograms TAMs and potentiates anti-PD-1 efficacy, further highlighting the tractability of these circuits (67, 68).
These pathways converge on T-cell signal deprivation and signaling interference: ARG1-mediated L-arginine depletion downregulates CD3ζ and arrests T-cell cycling, while iNOS-derived nitric oxide and peroxynitrite from MDSCs nitrates T-cell receptors and impairs antigen recognition, consolidating myeloid control over effector competence in CRC.
5 Reprogramming strategies targeting myeloid compartments
Therapeutic reprogramming of myeloid lineages in CRC aims to restore antigen presentation, diminish suppressive cytokine–eicosanoid–adenosine signaling, and reduce chemokine-driven exclusion of effector T cells. Macrophage-intrinsic phosphoinositide 3-kinase-γ (PI3Kγ) functions as a signaling switch that biases tumor-associated macrophages (TAMs) toward immunosuppression; pharmacologic PI3Kγ inhibition rebalances NF-κB/C/EBPβ programs, enhances antigen-presenting functions, and potentiates PD-(L)1 blockade in preclinical models, supporting clinical evaluation as a combinatorial partner (69, 70). Complementarily, targeting the CSF1–CSF1R axis reduces and re-educates suppressive TAM pools and increases intratumoral CD8+ T-cell infiltration. In CRC models, CSF1R inhibition augmented anti–PD-1 efficacy, indicating on-target remodeling of macrophage phenotypes (71, 72). However, CSF1R blockade can induce compensatory granulocytic recruitment through cancer-associated fibroblast chemokines, arguing for rational pairing with chemokine-axis inhibitors or T cell–priming agents to prevent myeloid rebound.
TREM2 defines an immunosuppressive TAM state that accumulates across solid tumors, including colorectal contexts. Genetic ablation or antibody blockade of TREM2 reorganizes the myeloid compartment toward inflammatory phenotypes, increases intratumoral T-cell activity, and synergizes with PD-1 blockade in vivo (73, 74). Mechanistic and translational studies further support TREM2 as a therapeutically tractable macrophage checkpoint; effector-enhanced anti-TREM2 antibodies and modalities delivering TREM2-directed binders into the tumor bed improve responses to PD-1 therapy, including in CRC models (75, 76). These position TREM2 antagonism as a candidate backbone for myeloid reprogramming in checkpoint-refractory CRC.
Granulocytic programs that enforce immune exclusion can be attenuated by interrupting chemokine-driven trafficking. In CRC, preclinical and early translational evidence supports blockade of IL-8/CXCL1/2–CXCR1/2 pathways to reduce neutrophil/PMN-MDSC accumulation and improve sensitivity to immune checkpoint blockade. Dual inhibition of CCR1 and CXCR2 curtailed myeloid recruitment and exhibited antitumor activity in colorectal settings, providing a strategy to counteract chemokine redundancy and stromal compensation observed with single-node targeting (77–80). Broader analyses of CXCR1/2 therapeutics corroborate that neutrophil-directed inhibition can be integrated with ICIs where granulocytic exclusion dominates (81, 82).
Metabolic and purinergic circuits that stabilize suppressive myeloid states are tractable points of intervention. COX-2–PGE2 signaling dampens dendritic-cell function, promotes regulatory myeloid outputs, and constrains T-cell priming; selective EP2/EP4 pathway inhibition or COX blockade reverses these effects in models, and early clinical experience combining COX inhibition with PD-1 in dMMR metastatic CRC indicates feasibility and activity, motivating expansion into pMMR disease (83, 84). In PMN-MDSCs, fatty-acid transport protein-2 (FATP2/SLC27A2) drives arachidonic-acid uptake and PGE2 synthesis; FATP2 inhibition abrogates granulocytic suppression and enhances checkpoint responses in vivo, nominating a selective strategy to disable neutrophil-dominant resistance (85, 86). The adenosinergic axis (CD39/CD73–A2A/A2B) tonically suppresses myeloid and lymphoid effector functions; co-blockade of CD73 and A2A receptors increases antitumor immunity and synergizes with ICIs in preclinical systems, and multiple agents targeting this pathway are under clinical evaluation (87, 88). Because macrophages, neutrophils, and MDSCs are also crucial for host defense and tissue repair, myeloid-targeted combinations may increase infection risk, delay wound healing, and trigger on-target inflammatory toxicities that must be carefully profiled in CRC trials.
6 Conclusion and outlook
Across colorectal cancer, convergent single-cell and spatial proteomic evidence identifies immunosuppressive myeloid programs as primary constraints on checkpoint inhibitor efficacy. SPP1high macrophages coupled to fibroblast-rich, TGF-β–dominant stroma, CXCR2-driven granulocytic circuits, and LAMP3+ mregDC modules form interconnected barriers that limit T-cell priming, trafficking, and effector function (89, 90). These populations assemble into reproducible cellular neighborhoods—particularly at the invasive front—where ligand–receptor density, matrix architecture, and chemokine gradients align to produce T-cell exclusion and checkpoint non-response. This integrated model explains why pMMR/MSS tumors rarely benefit from PD-(L)1 blockade and why even dMMR/MSI-H disease can be overridden by dominant myeloid axes.
Methodological advances now enable precise dissection of these states and their spatial context in clinical specimens. Joint RNA–protein single-cell profiling distinguishes closely related myeloid phenotypes and quantifies actionable surface molecules, while high-plex imaging resolves cell–cell proximities, gradients, and compartmentalized signaling. As shown in Table 1, these platforms provide complementary views of composition and topology and are sufficiently mature for biomarker development and pharmacodynamic assessment. Standardized panel design, segmentation quality control, and cross-batch normalization remain essential to ensure reproducibility across centers and trial cohorts.
Therapeutically, reprogramming—not ablation—of myeloid compartments emerges as the most generalizable path to synergy with PD-(L)1 blockade. Macrophage-intrinsic switches (PI3Kγ, TREM2), lineage-support pathways (CSF1–CSF1R), neutrophil trafficking axes (IL-8/CXCL1/2–CXCR1/2; CCR1/CCR2), and immunometabolic circuits (COX-2–PGE2; FATP2-dependent lipid handling; CD39/CD73–A2A/A2B adenosine signaling) constitute tractable nodes that can be combined to dismantle redundant suppressive loops. The preclinical and early translational signal across these targets supports a development strategy that prioritizes rational doublets with PD-(L)1 and favors mechanisms that simultaneously improve antigen presentation, restore chemokine balance, and reduce metabolite-mediated T-cell suppression (91, 92). Because pathway compensation is common, combinations that pair macrophage re-education with neutrophil-axis interruption, or that couple stromal TGF-β modulation with myeloid-targeted agents, are likely to be required in immune-excluded CRC.
Translation will depend on trial designs that embed single-cell and spatial endpoints. Neoadjuvant “window” studies and trials in metastatic CRC should use on-treatment biopsies to quantify state shifts in SPP1high TAMs, neutrophil/MDSC densities, mregDC prevalence, checkpoint-ligand distribution, and T-cell access to tumor nests. Peripheral biomarkers—such as circulating IL-8 and blood-derived myeloid signatures—can provide complementary, low-burden monitoring but should be analytically bridged to tissue-resolved readouts. Prospective stratification by stromal–myeloid architecture (e.g., mesenchymal/TGF-β–high niches) and by chemokine-axis activity will reduce biological heterogeneity and increase the likelihood of detecting true drug–drug interactions.
Looking forward, three priorities are clear. First, harmonized taxonomies of CRC myeloid states, grounded in cross-platform reference atlases, are needed to stabilize target selection and endpoint interpretation. Second, pharmacodynamic standards that tie quantitative remodeling of suppressive neighborhoods to clinical benefit should be codified and used to advance only those combinations that meet predefined tissue-based thresholds. Third, iterative co-development of drugs and diagnostics—integrating single-cell, spatial, and circulating measures—will be essential to match specific myeloid barriers with the most appropriate reprogramming strategies. By aligning mechanism, measurement, and patient selection, it should be possible to convert the immune-excluded colorectal tumor into a context receptive to checkpoint reinvigoration and to broaden durable benefit beyond the dMMR/MSI-H subset.
Author contributions
YD: Methodology, Conceptualization, Writing – original draft, Writing – review & editing. XL: Methodology, Conceptualization, Writing – original draft. LZ: Writing – review & editing, Conceptualization. JY: Writing – review & editing, Methodology, Conceptualization.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
CRC, colorectal cancer; ICIs, immune checkpoint inhibitors; dMMR, mismatch repair-deficient; MSI-H, microsatellite instability-high; pMMR, mismatch repair-proficient; MSS, microsatellite-stable; CMS, consensus molecular subtypes; TAMs, tumor-associated macrophages; MDSCs, myeloid-derived suppressor cells; mregDCs, mature dendritic cells enriched in immunoregulatory molecules; FAP, fibroblast activation protein; CODEX, co-detection by indexing; IMC, imaging mass cytometry; PI3Kγ, phosphoinositide 3-kinase-γ; FATP2, fatty-acid transport protein-2.
References
1. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. Pd-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. (2022) 386:2363–76. doi: 10.1056/NEJMoa2201445
2. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase iii keynote-177 study. Ann Oncol. (2025) 36:277–84. doi: 10.1016/j.annonc.2024.11.012
3. Tauriello DVF, Sancho E, and Batlle E. Overcoming tgfβ-mediated immune evasion in cancer. Nat Rev Cancer. (2022) 22:25–44. doi: 10.1038/s41568-021-00413-6
4. Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, et al. Single-cell and spatial analysis reveal interaction of fap(+) fibroblasts and spp1(+) macrophages in colorectal cancer. Nat Commun. (2022) 13:1742. doi: 10.1038/s41467-022-29366-6
5. Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. (2021) 184:4734–52.e20. doi: 10.1016/j.cell.2021.08.003
6. Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, et al. Immune cell topography predicts response to pd-1 blockade in cutaneous T cell lymphoma. Nat Commun. (2021) 12:6726. doi: 10.1038/s41467-021-26974-6
7. Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. (2023) 20:432–47. doi: 10.1038/s41423-023-00990-6
8. Li J, Zhou J, Huang H, Jiang J, Zhang T, and Ni C. Mature dendritic cells enriched in immunoregulatory molecules (Mregdcs): A novel population in the tumour microenvironment and immunotherapy target. Clin Transl Med. (2023) 13:e1199. doi: 10.1002/ctm2.1199
9. Lazennec G, Rajarathnam K, and Richmond A. Cxcr2 chemokine receptor - a master regulator in cancer and physiology. Trends Mol Med. (2024) 30:37–55. doi: 10.1016/j.molmed.2023.09.003
10. Sitaru S, Budke A, Bertini R, and Sperandio M. Therapeutic inhibition of cxcr1/2: where do we stand? Intern Emerg Med. (2023) 18:1647–64. doi: 10.1007/s11739-023-03309-5
11. Zhang J, Yin Y, Tang J, Zhang Y, Tian Y, and Sun F. Changes in serum interleukin-8 levels predict response to immune checkpoint inhibitors immunotherapy in unresectable hepatocellular carcinoma patients. J Inflammation Res. (2024) 17:3397–406. doi: 10.2147/jir.S460931
12. Esposito D, Napolitano F, Maresca DC, Scala M, Amato A, Belli S, et al. Early assessment of il8 and pd1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma. J Immunother Cancer. (2025) 13:e010421. doi: 10.1136/jitc-2024-010421
13. Kuswanto W, Nolan G, and Lu G. Highly multiplexed spatial profiling with codex: bioinformatic analysis and application in human disease. Semin Immunopathol. (2023) 45:145–57. doi: 10.1007/s00281-022-00974-0
14. Elhanani O, Ben-Uri R, and Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. (2023) 41:404–20. doi: 10.1016/j.ccell.2023.01.010
15. Glasson Y, Chépeaux LA, Dumé AS, Lafont V, Faget J, Bonnefoy N, et al. Single-cell high-dimensional imaging mass cytometry: one step beyond in oncology. Semin Immunopathol. (2023) 45:17–28. doi: 10.1007/s00281-022-00978-w
16. Mognol GP, Ghebremedhin A, and Varner JA. Targeting pi3kγ in cancer. Trends Cancer. (2025) 11:462–74. doi: 10.1016/j.trecan.2025.01.008
17. Tong X, Qiao S, Dong Z, Zhao X, Du X, and Niu W. Targeting csf1r in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications. J Nanobiotechnol. (2024) 22:409. doi: 10.1186/s12951-024-02584-4
18. Zhong J, Xing X, Gao Y, Pei L, Lu C, Sun H, et al. Distinct roles of trem2 in central nervous system cancers and peripheral cancers. Cancer Cell. (2024) 42:968–84.e9. doi: 10.1016/j.ccell.2024.05.001
19. Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High systemic and tumor-associated il-8 correlates with reduced clinical benefit of pd-L1 blockade. Nat Med. (2020) 26:693–8. doi: 10.1038/s41591-020-0860-1
20. Juric V, Mayes E, Binnewies M, Lee T, Canaday P, Pollack JL, et al. Trem1 activation of myeloid cells promotes antitumor immunity. Sci Transl Med. (2023) 15:eadd9990. doi: 10.1126/scitranslmed.add9990
21. Wei J, Zhang J, Wang D, Cen B, Lang JD, and DuBois RN. The cox-2-pge2 pathway promotes tumor evasion in colorectal adenomas. Cancer Prev Res (Phila). (2022) 15:285–96. doi: 10.1158/1940-6207.Capr-21-0572
22. Shen X, Cai Y, Li W, Shi L, Zhang J, Xie X, et al. Neoadjuvant pd-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (Picc): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial. EClinicalMedicine. (2025) 88:103499. doi: 10.1016/j.eclinm.2025.103499
23. Wu Z, Zhang Y, Cheng Y, Li J, Li F, Wang C, et al. Pd-1 blockade plus cox inhibitors in dmmr metastatic colorectal cancer: clinical, genomic, and immunologic analyses from the pcox trial. Med. (2024) 5:998–1015.e6. doi: 10.1016/j.medj.2024.05.002
24. Schiemann K, Belousova N, Matevossian A, Nallaparaju KC, Kradjian G, Pandya M, et al. Dual A2a/A2b adenosine receptor antagonist M1069 counteracts immunosuppressive mechanisms of adenosine and reduces tumor growth in vivo. Mol Cancer Ther. (2024) 23:1517–29. doi: 10.1158/1535-7163.Mct-23-0843
25. Sanders TJ, Nabel CS, Brouwer M, Hermant AL, Chaible L, Deglasse JP, et al. Inhibition of ent1 relieves intracellular adenosine-mediated T Cell suppression in cancer. Nat Immunol. (2025) 26:854–65. doi: 10.1038/s41590-025-02153-3
26. Allard D, Cormery J, Bricha S, Fuselier C, Abbas Aghababazadeh F, Giraud L, et al. Adenosine uptake through the nucleoside transporter ent1 suppresses antitumor immunity and T-cell pyrimidine synthesis. Cancer Res. (2025) 85:692–703. doi: 10.1158/0008-5472.Can-24-1875
27. Shi M, Ye L, Zhao L, He L, Chen J, Zhang J, et al. Tumor derived exosomal entpd2 impair cd8(+) T cell function in colon cancer through atp-adenosine metabolism reprogramming. Cell Commun Signal. (2024) 22:274. doi: 10.1186/s12964-024-01654-2
28. Le Naour A, Prat M, Thibault B, Mével R, Lemaitre L, Leray H, et al. Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. J Mol Cell Biol. (2020) 12:202–15. doi: 10.1093/jmcb/mjz090
29. Cambier S, Gouwy M, and Proost P. The chemokines cxcl8 and cxcl12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. (2023) 20:217–51. doi: 10.1038/s41423-023-00974-6
30. Matsushima K, Yang D, and Oppenheim JJ. Interleukin-8: an evolving chemokine. Cytokine. (2022) 153:155828. doi: 10.1016/j.cyto.2022.155828
31. Wang Y, Wang D, Yang L, and Zhang Y. Metabolic reprogramming in the immunosuppression of tumor-associated macrophages. Chin Med J (Engl). (2022) 135:2405–16. doi: 10.1097/cm9.0000000000002426
32. Sun Z, Qin Y, Liu D, Wang B, Jia Z, Wang J, et al. The evolution and functional characterization of cxc chemokines and receptors in lamprey. Dev Comp Immunol. (2021) 116:103905. doi: 10.1016/j.dci.2020.103905
33. You S, Li S, Zeng L, Song J, Li Z, Li W, et al. Lymphatic-localized treg-mregdc crosstalk limits antigen trafficking and restrains anti-tumor immunity. Cancer Cell. (2024) 42:1415–33.e12. doi: 10.1016/j.ccell.2024.06.014
34. Su A, Lee H, Tran M, Dela Cruz RC, Sathe A, Bai X, et al. The single-cell spatial landscape of stage iii colorectal cancers. NPJ Precis Oncol. (2025) 9:101. doi: 10.1038/s41698-025-00853-5
35. Wang F, Long J, Li L, Wu ZX, Da TT, Wang XQ, et al. Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer. Sci Adv. (2023) 9:eadf5464. doi: 10.1126/sciadv.adf5464
36. Semba T and Ishimoto T. Spatial analysis by current multiplexed imaging technologies for the molecular characterisation of cancer tissues. Br J Cancer. (2024) 131:1737–47. doi: 10.1038/s41416-024-02882-6
37. Liang W, Zhu Z, Xu D, Wang P, Guo F, Xiao H, et al. The burgeoning spatial multi-omics in human gastrointestinal cancers. PeerJ. (2024) 12:e17860. doi: 10.7717/peerj.17860
38. Ghebremedhin A and Varner JA. Pi3kγ in tumour inflammation: bridging immune response and cancer progression-a mini-review. Immunology. (2025) 176:215–23. doi: 10.1111/imm.13959
39. Colonna M. The biology of trem receptors. Nat Rev Immunol. (2023) 23:580–94. doi: 10.1038/s41577-023-00837-1
40. Reggio A, Fuoco C, Deodati R, and Palma A. Spp1 macrophages across diseases: A call for reclassification? FASEB J. (2025) 39:e70448. doi: 10.1096/fj.202403227R
41. Karol AB, Fujiwara Y, D’Ovidio T, Baldwin E, Joshi H, Doroshow DB, et al. Peripheral blood cytokines and outcomes with immune checkpoint blockade: A systematic review and meta-analysis. Immunotherapy. (2024) 16:829–40. doi: 10.1080/1750743x.2024.2379230
42. Yang F, Yao J, Tong X, Luo X, Liu Q, and Zhu W. Plasma il-6, il-8 and il-10 as predictors of response to pd-1 blockade immunochemotherapy in advanced gastric cancer. Clin Exp Med. (2025) 25:331. doi: 10.1007/s10238-025-01879-6
43. Zhao H, Wei S, Zhou D, Liu Y, Guo Z, Fang C, et al. Blocking the cxcl1-cxcr2 axis enhances the effects of doxorubicin in hcc by remodelling the tumour microenvironment via the nf-Kb/il-1β/cxcl1 signalling pathway. Cell Death Discov. (2023) 9:120. doi: 10.1038/s41420-023-01424-y
44. Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr., Hansen AR, et al. Cxcr2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: A phase 2 randomized trial. Invest New Drugs. (2024) 42:145–59. doi: 10.1007/s10637-023-01410-2
45. Chu X, Pu N, Yang X, Xie Y, Liu L, and Jin Y. Subtypes of tumor-associated neutrophils and their roles in cancer immunotherapy. Crit Rev Oncol Hematol. (2025) 212:104763. doi: 10.1016/j.critrevonc.2025.104763
46. Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, et al. Neoadjuvant pd-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (Picc): A single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. (2022) 7:38–48. doi: 10.1016/s2468-1253(21)00348-4
47. Wang Z, Wang X, Zhang X, Leng J, Cui M, Zhang J, et al. Toripalimab, bevacizumab, and irinotecan in dmmr/msi locally advanced colorectal cancer: first-stage results from a phase 1b/2 trial. Cell Rep Med. (2025) 6:102296. doi: 10.1016/j.xcrm.2025.102296
48. Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, et al. Coast: An Open-Label, Phase Ii, Multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage iii non-small-cell lung cancer. J Clin Oncol. (2022) 40:3383–93. doi: 10.1200/jco.22.00227
49. Hamid MA, Pammer LM, Lentner TK, Doleschal B, Gruber R, Kocher F, et al. Immunotherapy for microsatellite-stable metastatic colorectal cancer: can we close the gap between potential and practice? Curr Oncol Rep. (2024) 26:1258–70. doi: 10.1007/s11912-024-01583-w
50. Chiarella AM, Ryu YK, Manji GA, and Rustgi AK. Extracellular atp and adenosine in cancer pathogenesis and treatment. Trends Cancer. (2021) 7:731–50. doi: 10.1016/j.trecan.2021.04.008
51. Xu JG, Chen S, He Y, Zhu X, Wang Y, Ye Z, et al. An antibody cocktail targeting two different cd73 epitopes enhances enzyme inhibition and tumor control. Nat Commun. (2024) 15:10872. doi: 10.1038/s41467-024-55207-9
52. Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, and Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol. (2024) 21:147–64. doi: 10.1038/s41571-023-00846-y
53. Chen M, Ma H, Sun X, Schwartz M, Brand RE, Xu J, et al. Multimodal whole slide image processing pipeline for quantitative mapping of tissue architecture and tissue microenvironment. NPJ Imaging. (2025) 3:26. doi: 10.1038/s44303-025-00088-w
54. Hartmann FJ and Bendall SC. Immune monitoring using mass cytometry and related high-dimensional imaging approaches. Nat Rev Rheumatol. (2020) 16:87–99. doi: 10.1038/s41584-019-0338-z
55. Wu C, Zhang G, Wang L, Hu J, Ju Z, Tao H, et al. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma. Oncogene. (2024) 43:2751–67. doi: 10.1038/s41388-024-03123-z
56. Kvedaraite E and Ginhoux F. Human dendritic cells in cancer. Sci Immunol. (2022) 7:eabm9409. doi: 10.1126/sciimmunol.abm9409
57. Liu Y, Sinjab A, Min J, Han G, Paradiso F, Zhang Y, et al. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell. (2025) 43:905–24.e6. doi: 10.1016/j.ccell.2025.03.004
58. Fasano M, Pirozzi M, Miceli CC, Cocule M, Caraglia M, Boccellino M, et al. Tgf-B Modulated pathways in colorectal cancer: new potential therapeutic opportunities. Int J Mol Sci. (2024) 25:7400. doi: 10.3390/ijms25137400
59. Liner AG, van Gogh M, Roblek M, Heikenwalder M, and Borsig L. Non-redundant roles of the ccr1 and ccr2 chemokine axes in monocyte recruitment during lung metastasis. Neoplasia. (2025) 59:101089. doi: 10.1016/j.neo.2024.101089
60. Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, et al. Eganelisib, a first-in-class pi3kγ Inhibitor, in patients with advanced solid tumors: results of the phase 1/1b mario-1 trial. Clin Cancer Res. (2023) 29:2210–9. doi: 10.1158/1078-0432.Ccr-22-3313
61. Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B, Kyriakopoulos CE, et al. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. (2024) 42:179–84. doi: 10.1007/s10637-024-01419-1
62. Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, et al. First-in-human study of oleclumab, a potent, selective anti-cd73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. (2023) 72:2443–58. doi: 10.1007/s00262-023-03430-6
63. Tolcher AW, Gordon M, Mahoney KM, Seto A, Zavodovskaya M, Hsueh CH, et al. Phase 1 first-in-human study of dalutrafusp alfa, an anti-cd73-tgf-B-trap bifunctional antibody, in patients with advanced solid tumors. J Immunother Cancer. (2023) 11:e005267. doi: 10.1136/jitc-2022-005267
64. Talebi F, Gregucci F, Ahmed J, Ben Chetrit N, B DB, Chan TA, et al. Updates on radiotherapy-immunotherapy combinations: proceedings of 8th annual immunorad conference. Oncoimmunology. (2025) 14:2507856. doi: 10.1080/2162402x.2025.2507856
65. Turk A, Mondaca S, Nervi B, Morris AD, Finer Z, and Holowatyj AN. Early-onset colorectal cancer: from genetic discovery to clinical innovation. Am Soc Clin Oncol Educ Book. (2025) 45:e473618. doi: 10.1200/edbk-25-473618
66. Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, et al. Inhibition of mdsc trafficking with sx-682, a cxcr1/2 inhibitor, enhances nk-cell immunotherapy in head and neck cancer models. Clin Cancer Res. (2020) 26:1420–31. doi: 10.1158/1078-0432.Ccr-19-2625
67. Horn LA, Lind H, Fousek K, Qin H, Rajabian N, Angstadt S, et al. Inhibition of the chemokine receptors cxcr1 and cxcr2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of hpv-negative head and neck cancer models. J Exp Clin Cancer Res. (2024) 43:318. doi: 10.1186/s13046-024-03240-3
68. Meden A, Claes S, Van Loy T, Zorman M, Proj M, Schols D, et al. Structure-activity relationship study of navarixin analogues as dual cxcr2 and ccr7 antagonists. Bioorg Chem. (2025) 159:108423. doi: 10.1016/j.bioorg.2025.108423
69. Zhang Y, Ji S, Miao G, Du S, Wang H, Yang X, et al. The current role of dendritic cells in the progression and treatment of colorectal cancer. Cancer Biol Med. (2024) 21:769–83. doi: 10.20892/j.issn.2095-3941.2024.0188
70. Wang H, Zhou F, Qin W, Yang Y, Li X, and Liu R. Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics. (2025) 15:2159–84. doi: 10.7150/thno.105276
71. Wang Z, Du X, Xing X, Xie W, Xin H, and Liu W. Myeloid-derived suppressor cells: orchestrators of tumor immune evasion and therapeutic vulnerabilities. Mol Cancer Res. (2025) 23:829–38. doi: 10.1158/1541-7786.Mcr-25-0251
72. Goossens P, Lu C, Cao J, Gijbels MJ, Karel JMH, Wijnands E, et al. Integrating multiplex immunofluorescent and mass spectrometry imaging to map myeloid heterogeneity in its metabolic and cellular context. Cell Metab. (2022) 34:1214–25.e6. doi: 10.1016/j.cmet.2022.06.012
73. Gong D, Arbesfeld-Qiu JM, Perrault E, Bae JW, and Hwang WL. Spatial oncology: translating contextual biology to the clinic. Cancer Cell. (2024) 42:1653–75. doi: 10.1016/j.ccell.2024.09.001
74. Bollhagen A, Whipman J, Coelho R, Heinzelmann-Schwarz V, Jacob F, and Bodenmiller B. High-Resolution imaging mass cytometry to map subcellular structures. Nat Methods. (2025) 22:2601–8. doi: 10.1038/s41592-025-02889-8
75. Schrom EC, McCaffrey EF, Sreejithkumar V, Radtke AJ, Ichise H, Arroyo-Mejias A, et al. Spatial patterning analysis of cellular ensembles (Space) finds complex spatial organization at the cell and tissue levels. Proc Natl Acad Sci U.S.A. (2025) 122:e2412146122. doi: 10.1073/pnas.2412146122
76. Russell SN, Demetriou C, Valenzano G, Evans A, Go S, Stanly T, et al. Induction of macrophage efferocytosis in pancreatic cancer via pi3kγ Inhibition and radiotherapy promotes tumour control. Gut. (2025) 74:825–39. doi: 10.1136/gutjnl-2024-333492
77. Deb PK, Maity P, Sarkar B, Venugopala KN, Tekade RK, and Batra S. Insights from clinical trials on a(2a) adenosine receptor antagonists for cancer treatment. ACS Pharmacol Transl Sci. (2025) 8:1498–512. doi: 10.1021/acsptsci.5c00057
78. Molgora M, Liu YA, Colonna M, and Cella M. Trem2: A new player in the tumor microenvironment. Semin Immunol. (2023) 67:101739. doi: 10.1016/j.smim.2023.101739
79. Martorana F, Colombo I, Treglia G, Gillessen S, and Stathis A. A systematic review of phase ii trials exploring anti-pd-1/pd-L1 combinations in patients with solid tumors. Cancer Treat Rev. (2021) 101:102300. doi: 10.1016/j.ctrv.2021.102300
80. Yang Y, Zhu L, Xu Y, Liang L, Liu L, Chen X, et al. The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. biomark Res. (2025) 13:75. doi: 10.1186/s40364-025-00784-0
81. Lin JR, Wang S, Coy S, Chen YA, Yapp C, Tyler M, et al. Multiplexed 3d atlas of state transitions and immune interaction in colorectal cancer. Cell. (2023) 186:363–81.e19. doi: 10.1016/j.cell.2022.12.028
82. Hickey JW, Agmon E, Horowitz N, Tan TK, Lamore M, Sunwoo JB, et al. Integrating multiplexed imaging and multiscale modeling identifies tumor phenotype conversion as a critical component of therapeutic T cell efficacy. Cell Syst. (2024) 15:322–38.e5. doi: 10.1016/j.cels.2024.03.004
83. Masui H, Kawada K, Itatani Y, Hirai H, Nakanishi Y, Kiyasu Y, et al. Synergistic antitumor activity by dual blockade of ccr1 and cxcr2 expressed on myeloid cells within the tumor microenvironment. Br J Cancer. (2024) 131:63–76. doi: 10.1038/s41416-024-02710-x
84. Lv Q, Zhang Y, Gao W, Wang J, Hu Y, Yang H, et al. Csf1r inhibition reprograms tumor-associated macrophages to potentiate anti-pd-1 therapy efficacy against colorectal cancer. Pharmacol Res. (2024) 202:107126. doi: 10.1016/j.phrs.2024.107126
85. Di Luccia B, Molgora M, Khantakova D, Jaeger N, Chang HW, Czepielewski RS, et al. Trem2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-pd-1 tumor immunotherapy. Sci Immunol. (2024) 9:eadi5374. doi: 10.1126/sciimmunol.adi5374
86. Blanchard L, Mijacika A, and Osorio JC. Targeting myeloid cells for cancer immunotherapy. Cancer Immunol Res. (2025) 13:1700–15. doi: 10.1158/2326-6066.Cir-25-0159
87. Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, et al. A reversible src-relayed cox2 inflammatory program drives resistance to braf and egfr inhibition in braf(V600e) colorectal tumors. Nat Cancer. (2023) 4:240–56. doi: 10.1038/s43018-022-00508-5
88. Fukuda Y, Kim SH, Bustos MA, Cho SN, Roszik J, Burks JK, et al. Inhibition of microsomal prostaglandin E2 synthase reduces collagen deposition in melanoma tumors and may improve immunotherapy efficacy by reducing T-cell exhaustion. Cancer Res Commun. (2023) 3:1397–408. doi: 10.1158/2767-9764.Crc-23-0210
89. Nocentini A, Capasso C, and Supuran CT. Small-molecule cd73 inhibitors for the immunotherapy of cancer: A patent and literature review (2017-present). Expert Opin Ther Pat. (2021) 31:867–76. doi: 10.1080/13543776.2021.1923694
90. Maity P, Ganguly S, and Deb PK. Therapeutic potential of adenosine receptor modulators in cancer treatment. RSC Adv. (2025) 15:20418–45. doi: 10.1039/d5ra02235e
91. Rannikko JH and Hollmén M. Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br J Cancer. (2024) 131:627–40. doi: 10.1038/s41416-024-02715-6
Keywords: cancer-associated fibroblasts, checkpoint resistance, colorectal cancer, immune checkpoint inhibitors, neutrophils, tumor-associated macrophages
Citation: Dai Y, Luo X, Zhang L and Yan J (2026) Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches. Front. Immunol. 16:1742654. doi: 10.3389/fimmu.2025.1742654
Received: 09 November 2025; Accepted: 15 December 2025; Revised: 11 December 2025;
Published: 06 January 2026.
Edited by:
Chunguang Guo, Chinese Academy of Medical Sciences and Peking Union Medical College, ChinaReviewed by:
Ke Xu, Chongqing General Hospital, ChinaCopyright © 2026 Dai, Luo, Zhang and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Li Zhang, emhhbmdsaUBzY3N6bHl5Lm9yZy5jbg==; Jin Yan, eWFuamluXzExMTFAMTYzLmNvbQ==
†These authors have contributed equally to this work